TuHURA Biosciences, Inc.
NASDAQ:HURABiotechnology
+$0.14 today
- Market cap
- $87.31M
- Beta
- 0.01
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.52
Volume 0.19M
Average 0.85M
HURA Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
TuHURA Biosciences, Inc.NASDAQ: HURA
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents broadly unchanged from a year ago
Cash & equivalents stood at $6.3M at the end of Q1 FY2026, up 1.3% from a year earlier and up 74.0% from the prior quarter. Over 3 fiscal years it compounded at -36.7% a year.
Context
- Cash & equivalents amounted to 21.2% of total assets at the end of Q1 FY2026, down 21.3 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +1.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 3.62M USD
- Year-over-year change
- -71.4%
- 4-year CAGR
- -10.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.62M | -71.4% |
| FY2024 | 2024-12-31 | 12.66M | +245.3% |
| FY2023 | 2023-12-31 | 3.67M | -74.3% |
| FY2022 | 2022-12-31 | 14.25M | +157.0% |
| FY2021 | 2021-12-31 | 5.55M | — |
Cash & Equivalents vs competitors
How HURA compares with its peers on the latest reported figures
- HURA's Mar 2026 cash & equivalents of $6.3M is the lowest of the 9 companies compared; the peer median is $41.16M.
- Its year-over-year change of +1.3% is the 6th highest of 9, against a peer median of +29.1%.
- Cash & equivalents amounts to 21.2% of total assets for HURA, versus a peer median of 45.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
IRDOpus Genetics, Inc. | Mar 2026 | $59.96M | +43.5% | +1.9% | 89.8% |
| Mar 2026 | $56.13M | +14.8% | -28.3% | 95.1% | |
| Mar 2026 | $51.8M | +71.7% | -25.4% | 38.8% | |
| Mar 2026 | $47.32M | -9.8% | -3.9% | 17.4% | |
| Mar 2026 | $35M | +89.3% | -74.4% | 18.8% | |
| Mar 2026 | $31.13M | +89.5% | -4.0% | 86.1% | |
| Mar 2026 | $29.83M | -49.3% | -34.5% | 25.4% | |
| Mar 2026 | $26.27M | -34.2% | -1.5% | 52.8% | |
| Mar 2026 | $6.3M | +1.3% | -36.7% | 21.2% | |
| Peer median (excluding HURA) | $41.16M | +29.1% | -14.7% | 45.8% | |
Competitors are the stored peer set for HURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5.55M | 14.25M | 3.67M | 12.66M | 3.62M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 101.42K | 334.44K | 222.7K | 0 |
| Inventory | 0 | 0 | 0 | 214.7K | 0 |
| Other Current Assets | 135.13K | 390.35K | 159.33K | 316.35K | 1M |
| Total Current Assets | 5.68M | 14.74M | 4.16M | 19.61M | 4.62M |
| Property, Plant & Equipment (Net) | 617.14K | 418.55K | 202.99K | 322.53K | 685.17K |
| Goodwill | 0 | 0 | 0 | 0 | 10.74M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 103.9K | 33.77K | 0 | 33.77K | 11.31M |
| Total Non-current Assets | 721.04K | 452.32K | 202.99K | 356.3K | 22.73M |
| Total Assets | 6.4M | 15.2M | 4.36M | 19.97M | 27.35M |
| Account Payables | 413.79K | 1.92M | 1.87M | 3.15M | 3.77M |
| Short-term Debt | 644.07K | 0 | 0 | 0 | 197.35K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 456K | 675K | 137K | 1.16M | 1.53M |
| Total Current Liabilities | 7.15M | 2.87M | 3.6M | 5.33M | 5.92M |
| Long-term Debt | 0 | 0 | 2.32M | 0 | 303.63K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 197.92K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 20.74K | 2.32M | 42.7K | 501.55K |
| Total Liabilities | 7.15M | 2.89M | 5.92M | 5.37M | 6.42M |
| Common Stock | 4.53K | 4.53K | 6.8K | 42.32K | 59.34K |
| Retained Earnings | (49.48M) | (59.16M) | (88.47M) | (111.12M) | (141.18M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (747.82K) | 12.3M | (1.56M) | 14.59M | 20.93M |
| Total Debt | 644.07K | 138.22K | 2.34M | 202.54K | 700.02K |
| Net Debt | (4.9M) | (14.11M) | (1.32M) | (12.45M) | (2.92M) |
TuHURA Biosciences, Inc.
NASDAQ:HURA
Intrinsic Alpha fair value
Locked
Current Price
$1.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.